Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.